Hubbry Logo
FOX proteinsFOX proteinsMain
Open search
FOX proteins
Community hub
FOX proteins
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
FOX proteins
FOX proteins
FOX proteins
View on Wikipedia
from Wikipedia
NMR solution structure of human Foxp1

FOX (forkhead box) proteins are a family of transcription factors that play important roles in regulating the expression of genes involved in cell growth, proliferation, differentiation, and longevity. Many FOX proteins are important to embryonic development.[1][2] FOX proteins also have pioneering transcription activity by being able to bind condensed chromatin during cell differentiation processes.[3]

There are 50 different FOX genes encoding FOX proteins in humans that are further divided into 19 subdivisions based on conserved sequence similarity.[4] The defining feature of FOX proteins is the forkhead box, a sequence of 80 to 100 amino acids forming a motif that binds to DNA. This forkhead motif is also known as the winged helix, due to the butterfly-like appearance of the loops in the protein structure of the domain.[5] FOX proteins are a subgroup of the helix-turn-helix class of proteins.

Biological roles

[edit]

FOX genes are key elements in many developmental and biological processes, including regulating the cell cycle, metabolism, apoptosis, immune control, and pluripotency of embryonic stem cells. Beginning in unicellular eukaryotes, FOX genes developed by means of duplication and evolutionary divergence to acquire specialized roles.[6] By binding to particular DNA sequences, these proteins control gene expression and so affect cellular differentiation and organogenesis.[4]

Many genes encoding FOX proteins have been identified. There are 50 FOX genes in humans, divided into 19 different subclasses from FOXA to FOXS, based on conserved sequences. These subdivisions have diverse functions across different tissues and biological processes and genes within a given subunit often exhibit functional similarities. For example, the FOXM genes encode proteins that are involved in cell cycle progression.[7] FOXC genes encode proteins that ensure normal embryonic development and play a key role in the growth and function of different organs.[8]

FOX proteins play an important role in apoptosis and function as tumor suppressors, removing damaged cells. This is done via a mitochondria-dependent pathway or a mitochondria-independent pathway. In the mitochondria-independent pathway, FOX proteins increase the expression of death receptor ligands such as Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL). In the mitochondria-dependent pathway, FOX proteins activate pro-apoptotic Bcl-2 family proteins.[9]

FOXM1 is a well-defined transcription factor controlling genes linked to cell cycle development, preserving cellular homeostasis.[10] FOXM1 promotes the entry of a cell into the S phase and ensures the cell undergoes mitosis properly. FOXM1 activity is regulated by proliferation and anti-proliferation signals.[11] FOXM1 is a highly expressed tumour repressor in growing cells and contributes to tumorigenesis when dysregulated.[citation needed] Phosphorylation events regulate FOXM1 activity by influencing its localization and transcriptional action.[4]

The FOXO1 gene is involved in maintaining the pluripotency of embryonic stem cells. FOXO1 regulates critical pluripotency associated genes such as OCT4, NANOG and SOX2 (Oct4 and Sox2 are Yamanaka factors) by occupying and activating their promoters. This function can be inhibited by the ATK protein kinase.[12] The FOXO genes also play a role in the regulation of metabolism. FOXO proteins translate insulin and growth factor signaling into physiological responses, including suppressing gene expression. FOXO1 is involved in promoting gluconeogenesis in the liver by interacting with PGC-1α. This interaction can be inhibited by phosphorylation events, where FOXO1 is removed from the nucleus.[13]

Some FOX genes are downstream targets of the hedgehog signaling pathway, which plays a role in the development of basal cell carcinomas. Members of class O (FOXO- proteins) regulate metabolism, cellular proliferation, stress tolerance and possibly lifespan. The activity of FoxO is controlled by post-translational modifications, including phosphorylation, acetylation and ubiquitination.[14]

Post-Translational Modifications

[edit]

Control of FOX protein activity, localization, and stability depends critically on post-translational modifications (PTMs). These modifications, including phosphorylation, methylation and acetylation, help FOX proteins respond to various cellular signals, thereby enabling them to mediate essential biological processes such as apoptosis, cell survival, and cell cycle progression.[10]

Among the primary PTMs influencing FOX proteins is phosphorylation. For instance, phosphorylation of FOXO proteins can drive their nuclear translocation in response to stress signals, which is necessary for starting apoptotic gene expression. This change allows FOXO proteins to mediate the stress reaction and control cell survival.[10] Additionally, under control by phosphorylation is FOXM1, a necessary component of cell cycle progression. Specifically, phosphorylation increases the transcriptional activity of FOXM1, so advancing cell cycle progression during DNA replication and mitosis, which is a process essential for appropriate cellular growth.[4]

Particularly in relation to the development of cancer and the way cells traverse their growth cycle, acetylation is particularly crucial in determining the function of FOXM1. Enzymes such as p300/CBP add acetyl groups to specific sites on the FOXM1 protein, thus this process occurs. Particularly, this happens at particular lysine residues, including K63, K422, K440, K603, and K614. FOXM1 is able to greatly increase its capacity to activate genes linked with DNA copying and cell division by means of acetylation. Remarkably, the degree of acetylation of FOXM1 varies during the cell cycle rather than being constant. It peaks in the S, G2, and M phases of the cell cycle—the times when cells are actively getting ready for division. During these phases, the acetylated form of FOXM1 can more readily attach to its target genes, helping the cell to move through the cell cycle. On the other hand, FOXM1 becomes less active in the G1 phase, and the degree of acetylation also falls here. This variation in acetylation serves as a timing mechanism to guarantee that FOXM1 only acts when the cell needs it. Regarding cancer, the stakes are even higher. Acetylation improves FOXM1's capacity to activate genes, helping cancer cells grow, survive, and repair their DNA. When FOXM1 cannot be acetylated, as is the case when mutations stop the process from happening, its capacity to activate genes reduces, as well as its capacity to cause the development of tumours. This is why scientists are looking at several approaches to interfere with FOXM1's acetylation in order to either stop or slow down cancer's spread. The focus of this process could create fresh paths for the evolution of the next treatments.[15]

Another post translational modification of the FOX protein involves adding methyl groups to specific amino acids.[16] These modifications play a crucial role in immune response, cancer progression, and aging by altering FOX protein functions through protein-level changes.[16]

Discovery

[edit]
Detlef Weigel in 2013

The founding member and namesake of the FOX family is the fork head transcription factor in Drosophila, discovered by German biologists Detlef Weigel and Herbert Jäckle.[17][18] Since then a large number of family members have been discovered, especially in vertebrates. Originally, they were given vastly different names (such as HFH, FREAC, and fkh), but in 2000 a unified nomenclature was introduced that grouped the FOX proteins into subclasses (FOXA-FOXS) based on sequence conservation.[19]

The discovery of the FOX gene family and its evolutionary significance was outlined in a 2009 study by Hannenhalli and Kaestner.[6] The researchers detailed how FOX genes, originating in unicellular eukaryotes, evolved through gene duplication and loss events to form a complex family in mammals. This study also highlighted the diverse biological roles of FOX genes, including contributions to developmental processes such as organogenesis and speech acquisition, and their association with various diseases, including cancer and language disorders.[6]

Genes

[edit]

Cancer

[edit]

FOX genes must be under extreme evolutionary supervision in a genomic sequence or cis-acting elements. If not, they can lead to the development of many different types of cancer, including carcinoma, breast cancer, prostate cancer, and acute lymphocytic leukemia.[6]

Depending on the subfamily, the deregulation of FOX proteins is often associated with tumorigenesis and can act as a tumor suppressor or an oncogene.[22] Changes in post-translational modifications, genetic events, or oncoviruses are known causes for this deregulation.[22]

FOX proteins play critical roles in cellular homeostasis as they act as both tumor suppressors and oncogenes depending on the context. Dysregulation of FOX proteins may also contribute to diseases such as neurodevelopmental disorders and metabolic syndromes.[23] For example, FOXM1 is essential for cell cycle progression and is frequently over-expressed in tumors while FOXO proteins regulate apoptosis and stress responses indicating they often act as tumor suppressors.[23]

A member of the FOX family, FOXD2, has been detected progressively over-expressed in human-papillomavirus-positive neoplastic keratinocytes derived from uterine cervical preneoplastic lesions at different levels of malignancy.[24] For this reason, this gene is likely to be associated with tumorigenesis and may be a potential prognostic marker for uterine cervical preneoplastic lesions progression.[24]

Additional FOX family members have also been implicated in cancer progression and metastasis. FOXP1 acts as a tumor suppressor in breast and prostate cancers while showing oncogenic traits in certain lymphomas and leukemias.[25] FOXP3 which is crucial for regulatory T cell function has been shown to repress oncogenic pathways and exhibits tumor suppressive behaviour in breast and prostate cancers.[26]

FOXD2-AS1 is a long non-coding RNA related to the FOXD2 gene which serves as a potential biomarker in cancer. It is over-expressed in several malignancies including colorectal and gastric cancers and has been associated with poor prognosis and increased proliferation, invasion, and migration of cancer cells.[26][27]

FOXQ1 is found to promote epithelial-mesenchymal transition which is a process that promotes invasion and metastasis through the repression of epithelial markers such as E-cadherin and increases expression of mesenchymal genes. Over-expression of FOXQ1 has been linked to colorectal, gastric, and lung cancers, where it contributes to the tumor progression.[28][29]

FOXK2 has been linked to cancer and can function differently depending on the tissue type and molecular pathway it interacts with. In non-small-cell lung cancer, FOXK2 suppresses tumor progression by down-regulating cyclin D1 and CDKs allowing for the inhibition of cell proliferation and invasion.[30]

FOXO3a is another member that exhibits tissue-specific behaviour in cancer. In gastric cancer, its over-expression promotes invasion and migration by up-regulating cathepsin L which promotes epithelial-mesenchymal transition.[31] FOXO3a also acts as a tumor suppressor in nephroblastoma by inhibiting proliferation and invasion while inducing apoptosis.[32] In breast cancer, FOXO3a suppresses metastasis by down-regulating TWIST-1.[33]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

FOX proteins

View on Grokipedia
from Grokipedia
FOX proteins, also known as Forkhead box proteins, are a family of evolutionarily conserved transcription factors defined by a highly conserved known as the forkhead box or winged-helix domain, which enables specific recognition and binding to sequences. First identified in through the fkh gene, these proteins regulate diverse biological processes including embryonic development, cell differentiation, , and stress responses across from to humans. In humans and mice, the FOX family comprises 50 genes in humans and 44 in mice, classified into 19 subfamilies (FOXA through FOXS) based on sequence similarity within the forkhead domain and phylogenetic relationships. These transcription factors function as key regulators of gene expression by acting as activators or repressors, often in response to signaling pathways such as phosphatidylinositol 3-kinase (PI3K)/AKT and Wnt. Notable subfamilies include FOXA, which pioneer chromatin accessibility during tissue specification in organs like the liver and pancreas; FOXO, involved in insulin signaling, longevity, and tumor suppression; FOXM1, critical for cell cycle progression; and FOXP, essential for immune regulation and neural development, such as language acquisition via FOXP2. FOX proteins are indispensable for processes like gastrulation, stem cell maintenance, and organogenesis, with mutations or dysregulation leading to developmental defects. In disease contexts, FOX proteins exhibit dual roles as oncogenes or tumor suppressors; for instance, FOXM1 overexpression promotes proliferation in cancers like and , while FOXO inactivation contributes to metabolic disorders such as . They are also implicated in neurological conditions (e.g., Parkinson's via FOXA1/2) and autoimmune diseases (e.g., IPEX syndrome from mutations). Ongoing research highlights their therapeutic potential, including targeting FOXO for and FOXP3 for .

Fundamentals

Definition and Overview

FOX (forkhead box) proteins constitute a superfamily of transcription factors characterized by a conserved winged-helix that enables them to bind specific DNA sequences and regulate . This domain, approximately 100 in length, forms the structural hallmark of the family and facilitates their role as key regulators of transcriptional activity. The name "forkhead" originates from the founding member of the family, the fork head gene in , where mutations result in larvae exhibiting a forked cephalic structure due to defective head . These proteins are evolutionarily conserved across eukaryotes, from unicellular organisms like to complex multicellular species including humans, underscoring their fundamental biological importance. The number of FOX genes varies among species, with fungi encoding as few as four and mammalian genomes typically containing around 50, reflecting adaptive expansions and contractions over evolutionary time. In total, hundreds of FOX variants and isoforms have been identified across diverse eukaryotic lineages, highlighting the family's broad phylogenetic distribution. In general, FOX proteins orchestrate programs essential for cellular processes such as growth, proliferation, differentiation, and , thereby influencing organismal development and . Their conserved allows precise targeting of promoter and enhancer regions, modulating downstream pathways in response to environmental and developmental cues.

Structure and DNA Binding

The forkhead (FKH) domain, a hallmark of all FOX proteins, is a highly conserved DNA-binding motif comprising approximately 100 amino acids that folds into a winged-helix structure. This architecture features three α-helices (H1, H2, and H3) stacked in a bundle, with a three-stranded antiparallel β-sheet (S1, S2, and S3) forming the "wings" that extend from the base of the helices. The winged-helix configuration enables the domain to interact with DNA in a manner reminiscent of other transcription factors, such as those in the ETS family, while providing stability and specificity to the binding interface. DNA binding by the FKH domain primarily occurs through the insertion of the third α-helix (H3), known as the recognition helix, into the major groove of the DNA double helix. This helix makes base-specific contacts with a consensus sequence, typically 5′-GTAAA(T/C)AA-3′ (often represented as GTAAACAA), allowing FOX proteins to recognize and bind promoter or enhancer regions of target genes. The wings contribute additional interactions: wing 1 typically contacts the DNA phosphate backbone or minor groove, while wing 2 stabilizes the complex through non-specific electrostatic bonds, collectively ensuring high-affinity binding with sequence selectivity. Beyond the core FKH domain, FOX proteins often contain accessory domains that modulate their transcriptional activity. Many members, such as those in the FOXO subfamily, possess a C-terminal (TAD) rich in acidic residues that recruits coactivators like the complex to enhance . Inhibitory domains, frequently located in the N- or C-terminal regions, can auto-inhibit DNA binding or transactivation; for instance, the C-terminal region of FOXO proteins masks the TAD under certain conditions, preventing premature activation. Recent structural studies in 2025 have revealed variations in the winged-helix fold and wing conformations within certain FOX subfamilies, particularly in yeast homologs like Fkh1, which enhance DNA binding specificity. Unlike the canonical three-α-helix structure, Fkh1 features an extended fold with five α-helices and two β-strands, where wing 2 forms a stabilized loop via novel helices (H5 and H6) that enable base-specific contacts in the DNA minor groove's flanking regions. These adaptations, involving key residues like R400 and R401 for hydrogen bonding and salt bridges, allow for shape-mediated recognition beyond the core consensus site, as validated by molecular dynamics simulations and in vivo assays in Saccharomyces cerevisiae. Such variations suggest evolutionary diversification in binding mechanisms across FOX subfamilies, potentially influencing specificity in metazoan contexts.

Classification and Genetics

Subfamilies and Classification

The FOX proteins are systematically classified into 19 subfamilies, designated FOXA through FOXS, based on phylogenetic analysis of the sequences within their conserved forkhead . This classification reflects evolutionary divergence and structural similarities in the winged-helix motif of the domain, which determines DNA-binding specificity and protein interactions across metazoans. The standardized nomenclature, established by the , uses "FOX" followed by a capital letter indicating the subfamily (A–S) and an Arabic numeral for paralogous members within each subfamily, ordered by phylogenetic relatedness or order of identification (e.g., FOXA1, FOXA2, FOXO1, ). This system facilitates cross-species comparisons and highlights the conservation of the forkhead domain, a ~100-amino-acid region essential for classification. In vertebrates, the FOX family has undergone significant expansion through events, resulting in the encoding 49 FOX genes distributed across the 19 subfamilies, compared to 44 in the genome. Additionally, there are two known pseudogenes, FOXO1B and FOXO3B. Major subfamilies display distinctive structural features that underpin their classification: the FOXA subfamily includes proteins with a C-terminal domain enabling interaction, classifying them as pioneer factors; the FOXO subfamily features sites for post-translational modifications responsive to insulin signaling pathways; and the FOXP subfamily possesses a truncated wing 1 and elongated helical wing 2 in the forkhead domain, supporting dimerization and classification within immune-related contexts.

FOX Genes in Humans

The contains 49 FOX genes, classified into 19 subfamilies (FOXA through FOXS) based on sequence conservation within the forkhead domain and overall protein similarity. These genes are distributed across multiple chromosomes, with some clustering in genomic regions such as 6p25.3 (FOXC1, FOXF2, FOXQ1) and 16q24.1 (FOXC2, FOXF1, FOXL1). The following table catalogs all 49 human FOX genes along with their chromosomal loci, derived from current genomic annotations as of 2025.
GeneChromosomal Location
FOXA114q21.1
FOXA220p11.21
FOXA319q13.32
FOXB115q22.2
FOXB29q21.2
FOXC16p25.3
FOXC216q24.1
FOXD15q13.2
FOXD21p33
FOXD31p31.3
FOXD49p24.3
FOXD4L12q14.1
FOXD4L39q21.11
FOXD4L49q21.11
FOXD4L59q21.11
FOXD4L69p11.2
FOXE19q22.33
FOXE31p33
FOXF116q24.1
FOXF26p25.3
FOXG114q12
FOXH18q24.3
FOXI15q35.1
FOXI210q26.2
FOXI32p11.2
FOXJ117q25.1
FOXJ212p13.31
FOXJ31p34.2
FOXK17p22.1
FOXK217q25.3
FOXL116q24.1
FOXL23q22.3
FOXM112p13.33
FOXN117q11.2
FOXN22p16.3
FOXN314q31.3-q32.11
FOXN412q24.11
FOXO113q14.11
6q21
FOXO4Xq13.1
FOXO61p34.2
FOXP13p13
7q31.1
Xp11.23
FOXP46p21.1
FOXQ16p25.3
FOXR111q23.3
FOXR2Xp11.21
FOXS120q11.21
Human FOX genes exhibit a typical multi-exon structure, with most containing 3 to 15 exons and spanning 10 to 200 kilobases. The conserved forkhead domain, approximately 100 amino acids long, is generally encoded by one or two consecutive exons, preserving the winged-helix motif essential for DNA binding across the family. For instance, in FOXJ3, the domain spans exons 3 through 5, while in FOXP2, it occupies exons 12 to 14. Expression profiles of FOX genes display a range of tissue-specific and ubiquitous patterns, reflecting their diverse roles in cellular processes. The FOXA subfamily (FOXA1, FOXA2, FOXA3) is prominently expressed in endoderm-derived tissues, including the liver (high FOXA3), , and . In contrast, the FOXO subfamily (FOXO1, FOXO3, FOXO4, FOXO6) shows broad, near-ubiquitous expression, with elevated levels in insulin-responsive tissues such as liver, adipose, and for FOXO1. FOXP3 is restricted to immune cells, particularly regulatory T-cells in the and lymphoid tissues. Other examples include FOXJ1 in ciliated epithelia of the and FOXL2 in ovarian granulosa cells. Genetic variations in human genes primarily consist of common single nucleotide polymorphisms (SNPs), with thousands documented per in population databases. Many of these, particularly synonymous SNPs in coding regions or those in introns and promoters, are predicted to have neutral impacts on protein sequence, stability, or expression levels, as determined by computational pathogenicity scores like SIFT and PolyPhen-2. For example, in , several common intronic and synonymous SNPs show no association with functional alterations in structural analyses.

History and Discovery

Initial Discovery

The initial discovery of FOX proteins traces back to genetic studies in the fruit fly Drosophila melanogaster. In 1989, researchers identified the fork head (fkh) gene through mutants that exhibited severe defects in larval head structures, resembling a forked head due to the absence of anterior gut and cephalic structures. This was found to encode a nuclear protein expressed in the terminal regions of the , essential for gut and head development. In the same study, the of the Drosophila fork head protein was recognized as homologous to that of rat hepatocyte nuclear factor 3 (HNF3), marking HNF3 (now known as FOXA1) as the first identified mammalian forkhead protein. This conserved "forkhead domain," a winged-helix motif approximately 110 long, was proposed as a eukaryotic transcription factor DNA-binding structure shared across species. In the early , additional forkhead family members were cloned from tissues, expanding the family beyond liver-specific factors. For instance, brain factor 1 (BF-1, now FOXG1) was isolated from rat brain cDNA libraries in , revealing its restricted expression in the developing telencephalon and distinct DNA-binding specificity from HNF3 proteins. These findings highlighted the family's role in tissue-specific development and prompted systematic searches for more homologs. A standardized for the growing family was established in 2000 by the Vertebrate Winged Helix/Forkhead Box Nomenclature Committee under the Human Genome Organization, designating the genes as (forkhead box) followed by a letter (e.g., FOXA, FOXG) and a number based on phylogenetic relationships within the forkhead domain. This unified system replaced disparate historical names like HNF3 and BF-1, facilitating and research across .

Evolution of Research

Following the initial discovery of the forkhead gene in in the 1980s, research on FOX proteins advanced significantly in the early with the completion of the sequencing project in 2003, which enabled the comprehensive identification of the full FOX gene repertoire. This effort revealed approximately 50 FOX genes in humans, organized into 19 subfamilies, providing a complete catalog that facilitated systematic studies of their evolutionary conservation and diversification across species. Concurrently, approaches, including microarray-based expression profiling, began linking FOX proteins to key developmental processes, such as and tissue specification, highlighting their roles as conserved regulators in multicellular organisms. The 2010s marked a shift toward high-throughput genomic techniques, with chromatin immunoprecipitation followed by sequencing (ChIP-seq) emerging as a pivotal method for mapping FOX binding sites across the genome. Studies using ChIP-seq on various FOX family members, such as FOXO3, FOXK2, and FOXM1, demonstrated their sequence-specific DNA interactions and cooperative binding with other transcription factors, revealing dynamic regulatory networks at enhancers and promoters. These genome-wide analyses, often integrated with RNA-seq data, uncovered context-dependent binding patterns that varied by cell type and condition, advancing understanding of FOX-mediated transcriptional control beyond isolated gene targets. In the 2020s, single-cell RNA sequencing (scRNA-seq) has further refined FOX protein research by enabling resolution of their expression heterogeneity in complex tissues, such as the developing and immune cells. For instance, scRNA-seq applications have elucidated FOXP1's in striatal neuron diversification, identifying cell-type-specific regulatory modules during early postnatal development. Parallel advances in , particularly cryo-electron microscopy (cryo-EM), have provided atomic-level insights into FOX-DNA interactions; a 2024 cryo-EM study of the FOXA1- complex revealed mechanisms of through cooperative binding with GATA4, involving nucleosome repositioning and DNA bending. These techniques have underscored FOX proteins' intrinsic pioneering activity in opening compacted . Interdisciplinary approaches have increasingly integrated FOX studies with and , modeling their interactions within broader regulatory landscapes. FOX factors, such as FOXA and FOXO, recruit chromatin-modifying complexes like to alter marks and , facilitating stable epigenetic memory at developmental enhancers. Systems-level analyses, combining multi-omics data, have mapped FOX-centered networks that bridge signaling pathways (e.g., insulin/IGF-1) with , revealing emergent properties in cellular decision-making and . By 2025, these integrative frameworks continue to drive hypotheses on FOX dynamics in physiological contexts, leveraging computational simulations to predict network perturbations.

Biological Functions

Roles in Development

FOXA proteins, particularly FOXA1 and FOXA2, function as pioneer transcription factors that initiate chromatin accessibility during early embryonic development of endoderm-derived organs such as the liver and lungs. By binding to compacted chromatin and recruiting additional factors, FOXA factors open enhancers and promoters, enabling the expression of genes critical for organ specification and differentiation. In liver development, FOXA2 is essential for the initial commitment of definitive endoderm to hepatic fate, acting upstream of genes like Gata4 and Hnf4a to drive hepatoblast proliferation and maturation. Similarly, in lung development, FOXA2 promotes alveolar epithelial differentiation by facilitating the transition from pseudoglandular to canalicular stages, ensuring proper branching morphogenesis and surfactant production. FOXG1, a member of the FOXG subfamily, plays a pivotal role in patterning the telencephalon and maintaining neural progenitor pools during development. Expressed in the ventral telencephalon, FOXG1 represses dorsalizing signals while promoting ventral identity through interactions with BMP and Wnt pathways, thereby establishing the subpallium and regulating the balance between proliferation and . It sustains neural progenitor maintenance by inhibiting premature differentiation and supporting progression in the ventricular zone, ensuring sufficient progenitor expansion for cortical layering. Dysregulation of FOXG1, such as through , disrupts these processes, leading to congenital brain malformations including and . FOXP2, from the FOXP subfamily, contributes to the development of neural circuits underlying complex motor behaviors and skeletal . In the , FOXP2 is expressed in cortico-basal ganglia circuits during mid-gestation, where it modulates and connectivity essential for sequencing orofacial movements and vocalization learning, as observed in models analogous to human speech circuits. Beyond neural development, FOXP2 influences limb by regulating proliferation and joint maintenance in the hindlimbs, impacting skeletal integrity and motor function.

Roles in Metabolism and Homeostasis

The FOXO subfamily of proteins serves as key effectors in the insulin/insulin-like growth factor-1 (IGF-1) signaling pathway, integrating nutrient availability cues to regulate metabolic processes. In response to insulin or IGF-1 stimulation, the PI3K/AKT pathway phosphorylates FOXO proteins (FOXO1, FOXO3, FOXO4, and FOXO6), promoting their sequestration in the cytoplasm via 14-3-3 binding and inhibiting nuclear translocation. Conversely, under conditions of nutrient deprivation or low insulin signaling, inhibition of PI3K/AKT allows dephosphorylated FOXO proteins to translocate to the nucleus, where they activate transcription of genes involved in . FOXO proteins promote in hepatocytes by upregulating target genes such as G6PC (glucose-6-phosphatase) and PEPCK1 ( 1), which facilitate hepatic glucose production during states. This mechanism ensures maintenance of glucose levels when external supply is limited. Additionally, FOXO factors, particularly FOXO1 and , induce —a catabolic process for cellular recycling—by directly regulating genes like LC3 ( 1 light chain 3), which is essential for formation and degradation of damaged organelles. This autophagic response enhances cellular survival under metabolic stress. In the context of physiological , FOXA proteins play a pivotal role in and within hepatocytes. FOXA2, acting as a pioneer , binds to to activate genes encoding transporters such as SLC27A5 (very long-chain synthetase) and ABCC2 (), thereby maintaining and preventing . FOXA1 and FOXA2 also regulate by promoting β-oxidation and through targets like HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2), while suppressing accumulation via downregulation of lipogenic enzymes such as GPAT1 and DGAT2. These actions support adaptive responses to dietary and . FOXO3 contributes to systemic by enhancing stress resistance and , a function conserved across species as exemplified by its ortholog DAF-16 in . In worms, DAF-16 activation under reduced insulin signaling upregulates antioxidant genes like superoxide dismutases and catalases, conferring resistance to oxidative, thermal, and pathogenic stresses while extending lifespan by up to twofold in insulin receptor mutants. In mammals, FOXO3 similarly promotes through stress-responsive gene networks, linking metabolic regulation to organismal resilience.

Other Cellular Functions

FOXP3 serves as the master regulator of regulatory T cells (Tregs), a subset of + T cells critical for maintaining and preventing . By binding to the promoters of target genes such as CTLA4, which encodes a key inhibitory receptor on Tregs, FOXP3 suppresses effector T cell activation and promotes immunosuppressive functions, thereby inducing . This regulatory mechanism is essential for FOXP3+ Tregs to control immune responses in lymphoid tissues and mucosal surfaces. In the , FOXJ1 plays a pivotal role in ciliogenesis, the process of motile cilia formation in airway epithelial cells, which is indispensable for . FOXJ1 transcriptionally activates genes encoding structural components of cilia, such as dyneins and tubulins, enabling coordinated ciliary beating that propels mucus and trapped pathogens out of the . Disruptions in FOXJ1 expression impair this clearance mechanism, highlighting its specificity to ciliated cell differentiation in the lung and other mucociliary epithelia. FOXO proteins contribute to stem cell maintenance by enforcing quiescence and facilitating , particularly in hematopoietic stem cells (HSCs). For instance, FOXO1, along with and FOXO4, maintains HSC by repressing progression and protecting against oxidative stress-induced damage, ensuring long-term hematopoietic regeneration. In response to DNA lesions, FOXO factors upregulate repair pathways, such as those involving and , thereby preserving genomic integrity in quiescent HSCs. FOXO proteins also regulate and through transcriptional upregulation of pro-apoptotic and arrest genes. In stress conditions, FOXO binds to the BIM promoter, inducing expression of this BH3-only protein to trigger mitochondrial outer membrane permeabilization and activation, thereby promoting . For , FOXO activates p21 (CDKN1A), a inhibitor that halts proliferation in response to DNA damage or signaling, contributing to the stable exit characteristic of senescent states. These functions underscore FOXO's role in balancing cell survival and elimination to prevent tumorigenesis and tissue dysfunction.

Regulation

Transcriptional and Epigenetic Regulation

The expression of FOX proteins is tightly controlled at the transcriptional level by upstream transcription factors that bind to their promoters and enhancers. For instance, in regulatory T cells, the transcription factor NF-κB, particularly its p65 subunit, transactivates the proximal promoter of FOXP3 in response to T cell receptor signaling involving protein kinase C, thereby promoting FOXP3 expression essential for Treg differentiation. Similarly, other FOX family members, such as FOXO1, are regulated through feedback loops where FOXO factors bind to their own promoters to autoregulate expression; FOXO3a, for example, upregulates its own transcription via a positive autoregulatory loop in response to oxidative stress, enhancing cellular resilience. MicroRNAs also contribute to transcriptional control by indirectly suppressing FOX gene expression; miR-96 targets the 3' untranslated region of FOXO1 mRNA, leading to its post-transcriptional degradation and reduced protein levels, which in turn diminishes FOXO1-mediated transcription of target genes. Epigenetic mechanisms further modulate FOX protein activity by altering chromatin accessibility and gene silencing. FOXA factors, known as pioneer transcription factors, initiate chromatin opening by binding to nucleosomal DNA and facilitating histone acetylation, such as H3K27ac, which promotes an open chromatin state for subsequent transcription factor recruitment and gene activation during development and differentiation. Conversely, deacetylation events, mediated by histone deacetylases, can restrict FOXA binding and activity, maintaining repressive chromatin configurations. DNA methylation provides another layer of epigenetic control, often silencing FOX genes; hypermethylation of the FOXD3 promoter, for example, represses its expression by blocking transcription factor access, a mechanism observed in cancer cells. These regulatory layers—transcriptional activation by upstream factors, autoregulatory feedback, miRNA-mediated suppression, and epigenetic modifications—ensure precise spatiotemporal control of FOX protein levels, enabling their diverse roles in cellular processes.

Post-Translational Modifications

Post-translational modifications (PTMs) play a crucial role in regulating the activity, localization, and stability of FOX proteins, allowing rapid responses to cellular signals without altering gene expression levels. Among the FOX family, the FOXO subfamily is particularly well-studied for these dynamic covalent alterations, which fine-tune their function as transcription factors in processes like stress response and . These PTMs often intersect, such as influencing subsequent ubiquitination, to create layered control mechanisms. Phosphorylation, primarily mediated by the kinase AKT in response to insulin or growth factors, targets conserved serine and residues in FOXO proteins, promoting their inactivation through cytoplasmic sequestration. For instance, in FOXO1, AKT Thr24, Ser256, and Ser319, facilitating binding to 14-3-3 chaperone proteins that mask the nuclear localization signal and expose the , resulting in nuclear exclusion and reduced transcriptional activity. Similar sites in (Thr32, Ser253, Ser315) and FOXO4 (Thr28, Ser193, Ser258) elicit comparable effects, whereas FOXO6 lacks a and remains nuclear despite at Thr26 and Ser184. These modifications exemplify how integrates nutrient and growth signals to suppress FOXO-mediated . Acetylation modifies lysine residues in the DNA-binding and transactivation domains of FOXO proteins, generally inhibiting their function by disrupting DNA interactions or promoting cytoplasmic retention. The acetyltransferases CBP and p300 acetylate FOXO1 at sites including Lys262, Lys265, and Lys274, which reduces affinity for target DNA sequences and attenuates transcriptional activation, particularly under oxidative stress conditions. Conversely, the NAD+-dependent deacetylase SIRT1 removes these acetyl groups, restoring FOXO DNA binding and enhancing its pro-survival transcriptional output, as demonstrated in cellular models of stress where SIRT1 overexpression reactivates FOXO1 and FOXO3. This reversible acetylation cycle links FOXO activity to cellular energy status via NAD+ levels. Ubiquitination targets FOXO proteins for proteasomal degradation, providing a mechanism to attenuate their levels following prolonged signaling. The E3 ubiquitin ligase binds phosphorylated FOXO1 and , catalyzing their polyubiquitination and subsequent degradation, which depends on prior AKT to expose recognition motifs. This process is evident in insulin-stimulated cells, where MDM2-mediated ubiquitination reduces FOXO abundance, preventing excessive transcriptional repression of metabolic genes. Other PTMs, such as O-GlcNAcylation, connect FOXO function directly to glucose metabolism. This modification, catalyzed by O-GlcNAc transferase using UDP-GlcNAc derived from the hexosamine pathway, increases on FOXO1 in high-glucose environments, boosting its nuclear localization and transcriptional activation of gluconeogenic genes like G6PC, thus serving as a nutrient sensor to adapt hepatic glucose output.

Pathological Roles

Involvement in Cancer

FOX proteins exhibit dual roles in cancer, functioning as either oncogenes or tumor suppressors depending on the member and cancer type. The FOXO subfamily, particularly FOXO1, , and FOXO4, predominantly acts as tumor suppressors by promoting , arrest, and . In and cancers, FOXO inactivation often occurs through constitutive activation of the PI3K/AKT pathway, driven by mutations in PIK3CA or loss of PTEN, which leads to and nuclear exclusion of FOXO proteins, thereby suppressing their transcriptional activity and facilitating tumor progression. This inactivation is associated with poor prognosis, as restored FOXO activity can induce via upregulation of pro-apoptotic genes like BIM. In contrast, certain FOX proteins, such as FOXM1, function as oncogenes by driving and survival. FOXM1 is frequently overexpressed in (HCC), where it directly upregulates CCNB1, a involved in G2/M phase transition, thereby promoting uncontrolled cell division and tumor growth. This overexpression correlates with advanced disease stages and metastasis, highlighting FOXM1's role in oncogenic signaling networks. Similarly, FOXA1 serves as a pioneering lineage factor in estrogen receptor-positive (ER+) breast cancer, where its upregulation reprograms enhancers to activate prometastatic and contributes to endocrine therapy resistance. Recent advances as of 2025 have elucidated the FOX family's contributions to progression, with members like FOXM1 and FOXJ2 implicated in and chemoresistance. FOXM1 overexpression enhances tumor by modulating epithelial-mesenchymal transition, while FOXJ2 acts as a suppressor whose downregulation promotes proliferation and G1/S progression. Targeted inhibitors, such as the small-molecule FOXM1 antagonist STL001, have shown promise in sensitizing cells to by disrupting FOXM1-driven pathways, paving the way for combination therapies. These findings underscore the therapeutic potential of FOX-specific modulation, often linked to post-translational modifications like that alter protein localization and activity.

Roles in Other Diseases

FOXO1 dysregulation contributes significantly to the pathogenesis of type 2 diabetes, particularly through its persistent activation in the liver due to insulin resistance, which leads to excessive hepatic gluconeogenesis and hyperglycemia. In insulin-resistant states, FOXO1 fails to be adequately phosphorylated and excluded from the nucleus by insulin signaling, allowing it to transactivate genes such as G6PC and PEPCK, which encode key enzymes in gluconeogenesis. This mechanism exacerbates fasting hyperglycemia, a hallmark of type 2 diabetes, and studies in diabetic mouse models have shown that inhibiting FOXO1 activity restores glucose homeostasis by suppressing these gluconeogenic pathways. Mutations in the FOXP3 gene underlie immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, a severe autoimmune disorder characterized by early-onset multi-organ due to defective regulatory T-cell (Treg) function. FOXP3, a forkhead essential for Treg development and suppressive activity, when mutated, results in impaired FOXP3 protein expression or function, leading to uncontrolled T-cell activation, production, and inflammatory damage to tissues such as the gut, , and endocrine glands. Numerous distinct FOXP3 mutations (at least 70 as of 2016) have been identified in IPEX patients, predominantly affecting the DNA-binding forkhead domain or the proline-rich regulatory region, confirming FOXP3's critical role in maintaining . FOXG1 mutations are associated with a congenital variant of , a marked by severe , postnatal , seizures, and movement abnormalities resembling but distinct from classic Rett syndrome. These mutations, often de novo heterozygous loss-of-function variants, disrupt FOXG1's role as a transcriptional in early brain development, leading to abnormal corticogenesis and observed in affected individuals. Clinical phenotypes vary but commonly include infantile spasms and regression of acquired skills, with revealing simplified gyral patterns and ventricular enlargement. Polymorphisms in the FOXO3 have been consistently linked to and protection against cardiovascular diseases, with the G of rs2802292 serving as a longevity-associated variant that enhances FOXO3 expression and stress resistance. In older populations, carriers of longevity-associated FOXO3 genotypes exhibit reduced mortality from , attributed to FOXO3's anti-inflammatory and antioxidant effects in vascular cells that mitigate progression. Recent 2025 studies have further elucidated FOXO3's role in , demonstrating that its downregulation in promotes mitochondrial dysfunction and degradation, accelerating joint degeneration in obesity-related models. Activation of the p53-FOXO3 axis in articular has been shown to counteract these effects by enhancing and mitophagy, suggesting FOXO3 as a key modulator of chondrocyte aging and osteoarthritis susceptibility.

Therapeutic Potential

Targeting FOX Proteins in Therapy

Pharmacological modulation of proteins represents a promising therapeutic avenue for various diseases, leveraging their roles in cellular processes to either inhibit oncogenic activities or enhance suppressive functions. Strategies include small-molecule activators and inhibitors that target specific family members, often through upstream pathways or direct binding, with a focus on clinical translation in cancer and autoimmune disorders. Activation of FOXO proteins has been pursued for metabolic disorders like , where enhancing their nuclear localization promotes insulin sensitivity and glucose . AMPK agonists such as metformin achieve this by phosphorylating FOXO factors, facilitating their translocation to the nucleus to upregulate genes involved in stress resistance and longevity, thereby improving glycemic control in patients. Metformin, a first-line antidiabetic agent, indirectly supports FOXO activation via AMPK, demonstrating sustained benefits in reducing without direct FOXO targeting. In contrast, inhibition of FOXM1, an oncogene overexpressed in proliferating cancers, aims to block tumor growth by disrupting its transcriptional activity. Thiostrepton, a thiazole antibiotic, serves as a direct FOXM1 inhibitor that binds to its forkhead domain, preventing DNA binding and downstream gene expression essential for cell cycle progression and metastasis. Preclinical studies in ovarian and cholangiocarcinoma models show thiostrepton reduces tumor cell proliferation and enhances chemotherapy efficacy, such as with paclitaxel and cisplatin in ovarian cancer ascites, positioning it as a candidate for combination therapies in advanced solid tumors. Modulation of , the master regulator of regulatory T cells (Tregs), offers therapeutic potential in autoimmune diseases by boosting immunosuppressive function to restore . Low-dose interleukin-2 (IL-2) selectively expands and activates FOXP3+ Tregs through high-affinity signaling, increasing FOXP3 expression without overstimulating effector T cells. Clinical trials in conditions like systemic lupus erythematosus and have demonstrated that low-dose IL-2 safely enhances Treg numbers and function, leading to reduced disease activity and improved biomarkers of . Despite these advances, targeting FOX proteins faces significant challenges, particularly achieving isoform specificity amid family-wide redundancy and conserved DNA-binding domains. The structural similarity among FOX members often leads to off-target effects, complicating selective inhibition or activation, as compensatory mechanisms from related isoforms can mitigate therapeutic outcomes. Post-translational modifications, such as sites on FOXO proteins, offer druggable opportunities to fine-tune activity without broad family disruption. Emerging proteolysis-targeting chimeras (PROTACs) address these issues by inducing ubiquitin-mediated degradation of specific FOX proteins, with preclinical FOXM1-targeted PROTACs showing potent in cancer cells.

Current and Future Research

In 2025, AI-driven methods are advancing the prediction of FOX protein interactomes by leveraging architectures to model biomolecular complexes with high accuracy. Tools like 3 have demonstrated the ability to predict joint structures of protein-DNA and protein-protein interactions, facilitating the mapping of networks that include FOX family members. Concurrently, -based screens are uncovering FOX dependencies across cellular contexts; for instance, genome-wide CRISPR loss-of-function screens in primary human T cells have cataloged genetic regulators essential for FOXP3 induction during differentiation. Additionally, /Cas9 exon tiling approaches have revealed functional motifs in FOXO1 that modulate its transcriptional activity, highlighting context-specific vulnerabilities in metabolic and stress response pathways. Translational research on FOXO proteins as geroprotectors addresses key gaps in aging-related diseases, with preclinical studies emphasizing their role in mitigating and . FOXO-regulated , such as OSER1, have been shown to enhance mitochondrial and extend lifespan in model organisms by reducing oxidative damage. In chondrocytes, FOXO proteins maintain against age-associated degeneration, positioning them as candidates for interventions in and related conditions. Although direct clinical trials targeting FOXO activation remain limited, FOXO3a has emerged as a promising therapeutic focus for age-related eye diseases, where its modulation could preserve tissue function amid declining pathways. Emerging investigations are exploring FOX dynamics at unprecedented resolution through single-molecule techniques, revealing mechanistic insights into their regulatory behavior. Single-molecule multiparameter fluorescence spectroscopy has demonstrated that DNA binding controls the dimerization of the FOXP1 forkhead domain, influencing its cooperative interactions in chromatin. These approaches are extending to broader FOX family studies, enabling real-time visualization of transcription factor mobility and nucleosome engagement in live cells. Future prospects in FOX research center on , where of FOX variants informs cancer risk stratification. Genomic analyses have identified FOX family mutations, such as those in FOXE1, that elevate susceptibility through altered transcriptional control. Similarly, differential expression and variants in multiple FOX genes correlate with tumor progression across cancer types, supporting genotype-guided screening and prevention strategies. These findings underscore the potential for FOX-focused to tailor interventions, bridging basic discovery with clinical utility.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5201025/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3500164/
  3. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-0938-x
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2733165/
  5. https://humgenomics.biomedcentral.com/articles/10.1186/1479-7364-4-5-345
  6. https://www.pnas.org/doi/10.1073/pnas.89.18.8754
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8501956/
  8. https://journals.biologists.com/dev/article/143/24/4558/47609/Fox-transcription-factors-from-development-to
  9. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fox-proteins
  10. https://genesdev.cshlp.org/content/14/2/142.full
  11. https://www.sciencedirect.com/science/article/pii/S0969212605004338
  12. https://www.mdpi.com/2073-4409/8/9/966
  13. https://www.cell.com/fulltext/S0969-2126%2805%2900433-8
  14. https://www.sciencedirect.com/science/article/pii/S0167488910003113
  15. https://academic.oup.com/nar/article/49/6/3573/6134176
  16. https://www.sciencedirect.com/science/article/pii/S2665928X22000095
  17. https://academic.oup.com/nar/article/53/18/gkaf946/8262766
  18. https://www.pnas.org/doi/10.1073/pnas.1310430110
  19. https://www.genenames.org/data/genegroup/#!/group/508
  20. https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3820
  21. https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3821
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4021867/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5793224/
  24. https://anatomypubs.onlinelibrary.wiley.com/doi/10.1002/dvdy.20131
  25. https://omim.org/entry/605317
  26. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272625
  27. https://www.researchgate.net/publication/301217685_Common_Genetic_Variants_in_FOXP2_Are_Not_Associated_with_Individual_Differences_in_Language_Development
  28. https://doi.org/10.1016/0092-8674(89)90133-5
  29. https://pubmed.ncbi.nlm.nih.gov/1350202/
  30. https://www.cell.com/trends/genetics/abstract/S0168-9525%2803%2900111-2
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4770209/
  32. https://www.tandfonline.com/doi/full/10.1128/MCB.00881-12
  33. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-015-0696-z
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7137930/
  35. https://pubmed.ncbi.nlm.nih.gov/32130906/
  36. https://www.sciencedirect.com/science/article/pii/S1097276524005926
  37. https://pubmed.ncbi.nlm.nih.gov/39121853/
  38. https://www.sciencedirect.com/science/article/abs/pii/S1874939912000703
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4699037/
  40. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.202000034
  41. https://genesdev.cshlp.org/content/25/21/2227.full
  42. https://www.nature.com/articles/s41467-021-26950-0
  43. https://www.sciencedirect.com/science/article/pii/S0012160605002216
  44. https://journals.biologists.com/dev/article/137/9/1553/44292/FoxG1-and-TLE2-act-cooperatively-to-regulate
  45. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2019.00482/full
  46. https://www.ncbi.nlm.nih.gov/books/NBK604176/
  47. https://www.pnas.org/doi/10.1073/pnas.1721820115
  48. https://www.ncbi.nlm.nih.gov/books/NBK7023/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC5480241/
  50. https://www.researchgate.net/publication/7878511_FoxO_proteins_in_insulin_action_and_metabolism
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC6478346/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9927216/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC4095974/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7017163/
  55. https://www.sciencedirect.com/science/article/pii/S0531556515300498
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC6754763/
  57. https://www.pnas.org/doi/10.1073/pnas.0509484103
  58. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.865593/full
  59. https://www.sciencedirect.com/science/article/pii/S001216061630313X
  60. https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-14-70
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC5378048/
  62. https://www.sciencedirect.com/science/article/pii/S1934590907000835
  63. https://www.cell.com/fulltext/S0092-8674%2807%2900050-5
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC7012318/
  65. https://www.sciencedirect.com/science/article/pii/S0021925820407379
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC2387118/
  67. https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-021-00700-7
  68. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.13057
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC4160528/
  70. https://pubmed.ncbi.nlm.nih.gov/20462637/
  71. https://www.sciencedirect.com/science/article/pii/S2213231715000701
  72. https://pubmed.ncbi.nlm.nih.gov/26617698/
  73. https://www.nature.com/articles/s41586-023-06112-6
  74. https://pubmed.ncbi.nlm.nih.gov/31784734/
  75. https://pubmed.ncbi.nlm.nih.gov/15492844/
  76. https://www.nature.com/articles/s41419-023-06177-1
  77. https://www.cell.com/trends/biochemical-sciences/abstract/S0968-0004(04)00301-9
  78. https://www.sciencedirect.com/science/article/pii/S0021925819711260
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC2682847/
  80. https://pubmed.ncbi.nlm.nih.gov/18420577/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC4823058/
  82. https://erc.bioscientifica.com/downloadpdf/journals/erc/23/2/R113.pdf
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC5555100/
  84. https://pubmed.ncbi.nlm.nih.gov/29705704/
  85. https://pubmed.ncbi.nlm.nih.gov/31826955/
  86. https://pubmed.ncbi.nlm.nih.gov/31644911/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC12222324/
  88. https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-025-02270-7
  89. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1604998/full
  90. https://www.nature.com/articles/s41420-024-01929-0
  91. https://pubmed.ncbi.nlm.nih.gov/40746724/
  92. https://pubmed.ncbi.nlm.nih.gov/20736318/
  93. https://pubmed.ncbi.nlm.nih.gov/24238363/
  94. https://pubmed.ncbi.nlm.nih.gov/34058194/
  95. https://pubmed.ncbi.nlm.nih.gov/12819471/
  96. https://pubmed.ncbi.nlm.nih.gov/11137993/
  97. https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.13011
  98. https://pubmed.ncbi.nlm.nih.gov/22670136/
  99. https://pubmed.ncbi.nlm.nih.gov/19564653/
  100. https://pubmed.ncbi.nlm.nih.gov/22129046/
  101. https://pubmed.ncbi.nlm.nih.gov/25199915/
  102. https://www.nature.com/articles/s41514-024-00142-8
  103. https://www.nature.com/articles/s41467-025-59883-z
  104. https://pubmed.ncbi.nlm.nih.gov/40822516/
  105. https://www.sciencedirect.com/science/article/pii/S2950523225000375
  106. https://www.sciencedirect.com/science/article/pii/S1568163722000630
  107. https://www.sciencedirect.com/science/article/pii/S1048891X24020851
  108. https://www.sciencedirect.com/science/article/pii/S1936523325000580
  109. https://www.nature.com/articles/s41435-023-00221-y
  110. https://www.sciencedirect.com/science/article/abs/pii/S0896841115000025
  111. https://www.sciencedirect.com/science/article/pii/S1074761324003650
  112. https://www.sciencedirect.com/science/article/abs/pii/S0045206825005061
  113. https://www.nature.com/articles/s41586-024-07487-w
  114. https://pubmed.ncbi.nlm.nih.gov/40140585/
  115. https://www.researchgate.net/publication/386016867_Functional_Motif_Discovery_in_FOXO1_Through_CRISPRCas9_Exon_Tiling_Scan
  116. https://www.nature.com/articles/s41467-024-51542-z
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC12357264/
  118. https://www.sciencedirect.com/science/article/abs/pii/S002432052400359X
  119. https://www.cell.com/cell-reports-physical-science/pdf/S2666-3864%2824%2900079-1.pdf
  120. https://www.sciencedirect.com/science/article/abs/pii/S0304383512005666
  121. https://www.mdpi.com/2073-4425/13/10/1754
Add your contribution
Related Hubs
User Avatar
No comments yet.